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ABSTRACT  22 
Emerging research has demonstrated that pancreatic ductal adenocarcinoma (PDAC) contains a sub-23 
population of cancer stem cells (CSCs) characterized by self-renewal, anchorage-independent-growth, 24 
long-term proliferation and chemoresistance. The secretome analysis of pancreatic CSCs has not yet 25 
been performed, although it may provide insight into tumour/microenvironment interactions and 26 
intracellular processes, as well as to identify potential biomarkers.   27 
To characterize the secreted proteins of pancreatic CSCs, we performed an iTRAQ-based proteomic 28 
analysis to compare the secretomes of Panc-1 cancer stem-like cells (Panc1 CSCs) and parental cell line. 29 
A total of 72 proteins were found up-/down-regulated in the conditioned medium of Panc-1 CSCs. The 30 
pathway analysis revealed modulation of vital physiological pathways including glycolysis, 31 
gluconeogenesis and pentose phosphate pathway. 32 
Through ELISA immunoassays we analysed the presence of the three proteins most highly secreted by 33 
Panc-1 CSCs (ceruloplasmin, galectin-3, and MARCKS) in sera of PDAC patient. ROC curve analysis 34 
suggests ceruloplasmin as promising marker for patients negative for CA19-9. 35 
Overall, our study provides a systemic secretome analysis of pancreatic CSCs revealing a number of 36 
secreted proteins which participate in pathological conditions including cancer differentiation, invasion 37 
and metastasis. They may serve as a valuable pool of proteins from which biomarkers and therapeutic 38 
targets can be identified.  39 
 40 
 41 
 42 
 43 
44 
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Introduction 45 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and devastating human 46 
malignancies with a death-to-incidence ratio of 0.99. Most patients have metastatic disease at the time of 47 
diagnosis. More than 75% of patients who undergo surgical resection of small pancreatic tumours with 48 
clear surgical margins and no evidence of metastasis nonetheless die from metastasis within 5 years [1], 49 
a finding that is consistent with early spread. In addition to late diagnosis, high resistance to 50 
chemotherapy and radiation seems to be responsible for the dismal outcome of PDAC. Recent studies 51 
have demonstrated that in a mouse model of PDAC cellular dissemination leading to metastasis occurs 52 
prior to the formation of an identifiable primary tumour [2]. This behaviour is associated with epithelial-53 
to-mesenchymal transition (EMT) and with the establishment of circulating pancreatic cells which 54 
maintain a mesenchymal phenotype and express typical markers of cancer stem cells (CSCs) [3]. 55 
Evidence for the existence of CSCs has also been provided in primary human pancreatic 56 
adenocarcinomas grown in immunocompromised mice [4]. At the present, PDAC CSCs may be 57 
considered a subpopulation of cells in the bulk of the tumour characterised by the exclusive ability to 58 
drive tumourigenesis and metastasis and to play a fundamental role in disease relapse. Hence, to 59 
substantially impact long-term survival of PDAC patients, the study of the biological features and of the 60 
secretome of PDAC CSCs is critical, and will inform the development of more efficient therapies and 61 
the identification of early biomarkers. 62 
The high heterogeneity of CSCs, which originates from genotypic and phenotypic plasticity, and 63 
their low presence in cancer sample tissues make their isolation and correct identification extremely 64 
difficult, strongly limiting the realization of biochemical studies. The current approach to isolate CSCs 65 
from tissue samples is mainly based on the difference in cell size or on the expression of specific 66 
antigens. However, these methods do not permit the recovery of sufficient cells to perform proteome or 67 
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secretome studies. In order to obtain valid and reproducible results, the biochemical approach to CSC 68 
pathophysiology can take advantage of the observation that CSCs can be isolated and enriched from 69 
several human cancer cell lines [5]. Recently, our group has been able to isolate cancer stem-like cells 70 
from five out of nine PDAC cell lines [6]. In particular, we have demonstrated that Panc-1 cancer stem-71 
like cells (Panc1 CSCs) isolated from parental cell line by using the CSC selective medium, represent a 72 
model of great importance to deepen the understanding of the biology of pancreatic adenocarcinoma. 73 
Panc-1 CSCs showed the highest tumorsphere-forming ability, were more resistant to the action of the 74 
anticancer drugs, had typical surface stem cell markers, and when subcutaneously injected into nude 75 
female mice were more tumorigenic than parental cells. Thus far, proteomic approaches have been 76 
applied to pancreatic CSCs isolated from xenografted tumours in mice [7], early stage tumours [8], or 77 
established cell lines [9]. However, secretome analysis of pancreatic CSCs has not yet been reported, 78 
although the secreted proteins may serve as a valuable tool to obtain insight into interaction of the 79 
tumour with its microenvironment as well as intracellular processes, taking into account the observation 80 
that many tumour cells shed intracellular and even nuclear proteins into the extracellular space. 81 
Furthermore, these studies may allow the identification of potential PDAC biomarkers. Contrarily to 82 
PDAC, secretome approaches have been used to investigate CSCs of colon [10] and prostate cancer 83 
[11]. In general, secretome studies on cell lines grown in culture medium are limited by contamination 84 
from intracellular proteins originating from spontaneous cell autolysis. For this reason, a filtering 85 
criterion [12] must be established to select bona fide secreted proteins while avoiding the contaminants 86 
for downstream validation works. In this study, we have adopted a shotgun proteomics approach using 87 
iTRAQ 8-plex coupled with 2D-LC-MS/MS to compare the secretome of Panc1 pancreatic 88 
adenocarcinoma cell line with that of their derived stem-like cells (Panc1 CSCs). In order to identify 89 
only secreted proteins, we have compared the protein expression levels of the conditioned medium (CM) 90 
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with those of the whole cell lysate, taking into account that the relative abundance of secreted proteins 91 
should be higher in CM than in cell lysate. Following this approach, we have identified 43 proteins 92 
secreted at higher level by Panc1 CSCs relative to the parental cells. In silico functional pathway 93 
analysis has demonstrated a predominant association of these proteins to glycolysis, gluconeogenesis, 94 
IGF-1 signalling, atherosclerosis signalling, pyruvate fermentation to lactate, and pentose phosphate 95 
pathway. Among the identified proteins, ceruloplasmin was the most abundant detected in CM from 96 
Panc1 CSCs and showed promise as predictors for PDAC, particularly for patients negative for CA19-9.  97 
To our knowledge, this is the first proteomic study of pancreatic CSC secretome.  Our findings 98 
advance the understanding of the pathways implicated in tumourigenesis, metastasis and 99 
chemoresistance of pancreatic cancer, and also identify a pool of proteins from which novel candidate 100 
diagnostic and therapeutic biomarkers could be discovered. 101 
 102 
MATERIALS AND METHODS 103 
Cell culture  104 
The human PDAC cell line Panc1 was grown in RPMI 1640 supplemented with 10% FBS, 2 mM 105 
glutamine, and 50 µg/ml gentamicin sulfate (Gibco, Life Technologies). Adherent cells were maintained 106 
in standard conditions for a few passages at 37°C with 5% CO2. Panc1 CSCs were obtained as 107 
previously described [6]. Briefly, adherent cells were cultured in CSC medium (i.e. DMEM/F‑12 108 
supplemented with glucose, B27, fungizone, penicillin/streptomycin, heparin, epidermal growth factor 109 
and fibroblast growth factor) for at least 1‑3 weeks or until the appearance of tumorspheres, which were 110 
then cultured in CSC medium for at least three passages before initiating the experiments. 111 
 112 
Sample preparation   113 
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Panc1 cells and Panc1 CSCs were grown to ~70% confluence in 150 cm
2
 culture flasks, washed 114 
six times in serum-free RPMI and B27-free DMEM/F-12 medium, respectively, and then incubated in 115 
serum/B27-free medium for 22 h. Cell viability, determined with 0.4% trypan blue solution (Invitrogen), 116 
was higher than 95%. The media containing secreted proteins were collected by centrifugation at 1,000 x 117 
g for 10 min to pellet floating cells and were defined as conditioned media (CM). After the addition of 118 
1x protease inhibitor cocktail, CM were centrifuged again at 100,000 x g for 20 min at 4°C to pellet the 119 
remaining cell debris. Proteins in the CM were precipitated overnight at -20°C with 4 volumes of ice-120 
cold acetone. The pellets were then collected by centrifugation at 17,000 x g for 20 min at 4°C, 121 
resuspended in 0.5 M TEAB containing 0.1% SDS, and finally concentrated using 3kDa cut-off spin 122 
columns (Millipore). To obtain whole lysate samples, the cell pellets were collected and lysed in 0.5 M 123 
TEAB containing 0.1% SDS and 1x protease inhibitor cocktail. Cells were lysed by two steps of 124 
sonication (3 times for 10 sec) interposed with a step at -80°C for 30 min. Samples were then 125 
centrifuged at 14,000 x g for 10 min at 4°C to remove debris, and the supernatants were collected and 126 
stored at -80°C.  Protein concentrations were determined using BCA protein assay (Thermo Scientific).  127 
 128 
iTRAQ 8-plex labeling  129 
The iTRAQ 8-plex reagents were purchased from AB Sciex (Framingham, USA) and the 130 
labeling was carried out following the protocol provided by the manufacturer. A set of Panc1 whole cell 131 
lysate and CM samples and Panc1 CSC whole cell lysate and CM samples was labeled with iTRAQ 132 
reagent 113, 114, 115, and 116, respectively. A second biological replicate from a different cell culture 133 
passage was prepared and labeled in the same order with iTRAQ reagents 117, 118, 119, and 121.  134 
Briefly, samples were prepared to have 100 µg of proteins in a final volume of 25 µl. Two µl of 0.05 M 135 
tris-(2-carboxyethyl) phosphine (TCEP) Reducing Agent (Sigma) were added to each sample and the 136 
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mixture was incubated at 60°C for 1 h. Then, 1 µl of Cysteine Blocking Reagent (Iodoacetamide, 15 137 
mg/ml, Sigma) was added and the mixture was incubated at room temperature for 10 min. Finally, 10 µg 138 
of trypsin (Promega, Sequence Grade) were added to each tube and the samples were incubated at 37°C 139 
overnight for protein digestion. iTRAQ reagents were allowed to reach room temperature and 50 µl of 140 
isopropanol were added to each tube. Subsequently, the content of each iTRAQ reagent vial was 141 
transferred to each sample tube, and incubated for 2 h at room temperature. Finally, the labeled proteins 142 
were mixed and subjected to SCX chromatography to remove impurities and excess labels. The iTRAQ 143 
samples were diluted to 5 ml with diluent (10 mM potassium phosphate (KH2PO4), 25% acetonitirile), 144 
adjusted to pH 3 with H3PO4, and loaded onto a SCX chromatography column (4.6 x 200 mm, 145 
polysulfoethil A, PolyLC; Agilent 1200). Peptides were fractionated over a 90 min gradient at flow rate 146 
of 1 ml/min. Fractions (80 x 1ml) were collected at room temperature, vacuum dried and stored at 4°C. 147 
For de-salting processing of eluted fractions, each dried fraction was dissolved in 1 ml of 100% 148 
H2O:0.1%TFA and loaded onto a RP C18 column (Agilent 4.60 mm x 50 mm) using a Vision HPLC 149 
(Perseptive Biosystems, UK). Peptides were washed for 10 min with 0.1 % TFA and then rapidly eluted 150 
using 100% ACN:0.1%TFA at flow rate of 1.5 ml/min using in-line column switching. Each desalted 151 
fraction was dried overnight by vacuum centrifugation and stored at 4°C. 152 
 153 
LC-MS/MS analysis and data processing  154 
Desalted fractions were reconstituted in 40 L 0.1% formic acid and 5 L aliquots were 155 
delivered into a Triple TOF 5600 (AB Sciex) via an Eksigent NanoUltra cHiPLC System (AB Sciex) 156 
mounted with a microfluidic trap (200 µm x 500 µm ChromXP C18-CL 3 µm 300 Å) and analytical 157 
column (15 cm × 75 μm) packed with ChromXP C18−CL 3 μm. A NanoSpray III source was fitted with 158 
a 10 μm inner diameter SilicaTip emitter (New Objective, Woburn, USA). The trap column was washed 159 
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with 2% ACN/0.1% formic acid for 10 min at 2 μL/min. A gradient of 2−50% ACN/0.1%  formic acid 160 
(v/v) over 90 min was applied at a flow rate of 300 nL/min. Spectra were acquired automatically in 161 
positive ion mode using information-dependent acquisition powered by Analyst TF 1.5.1 software (AB 162 
Sciex). Up to 25 MS/MS spectra were acquired per cycle (approximately 10 Hz) using a threshold of 163 
100 counts per s and with dynamic exclusion for 12 s. The rolling collision energy was increased 164 
automatically by selecting the iTRAQ check box in Analyst, and manually by increasing the collision 165 
energy intercepts by 5. TOF-MS spectra were acquired for 250 ms (mass range 400−1650 Da) and 166 
MS/MS spectra for100 ms each (mass range 100−1400 Da). Mass spectrometer recalibration was 167 
performed at the start of every fifth sample using a β-galactosidase digest standard.  168 
Data analysis was performed using ProteinPilot software (Version 4.2, revision 1340, AB Sciex) 169 
using default settings and with bias and background correction applied. The data were searched against 170 
UniProt/SwissProt database (2013_2, total 30,309,316 entries, 40,464 human entries searched) using the 171 
Paragon algorithm (4.2.0.0, version 1304, AB Sciex). The mass tolerance for both precursor and 172 
fragment ions was 10ppm. ProteinPilot uses an algorithm for its peptide identifications wherein there is 173 
not an option to select the number of missed or non-specific cleavages per se. Instead, it searches the 174 
databases using probabilities of cleavages at different residues depending on the enzyme used (trypsin: 175 
after Arg probability of 0.9, after Lys 0.8, after Lys-Lys 0.7 etc.) [13]. It also performs initial database 176 
matching based on short sequence tags, rather than on parent ion m/z, which means it is acceptable to 177 
include peptides with missed or non-specific cleavages if they are identified with sufficient confidence. 178 
These will then contribute to the overall confidence of protein identification. The variable modifications 179 
selected for the search were ‘biological modifications’ (probability-based modification search of 461 180 
biological, chemical and artefactual modifications), while the fixed modifications were 181 
carbamidomethylation of cysteines, and iTRAQ modification of C-terminal lysine residues and peptide 182 
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N-termini. A global FDR value of 1% was used based on the number of proteins identified before 1% of 183 
the identifications were derived from a match to the reverse database [14] (equating to an unused score 184 
of 1.09 and a confidence of 91.9%). Similarly, a global FDR cut-off of 1% was used as the criterion for 185 
acceptance of individual MS/MS spectra and in this case corresponded to a confidence of 93.8%. Protein 186 
redundancy is also handled seamlessly in ProteinPilot via the ProGroup algorithm [13]. The software 187 
reports all peptides that contribute to protein identification, but the protein will only be listed in the 188 
results table if there are peptides unique to that protein within the dataset. Only unique peptides 189 
contribute to the quantification. The exception is when there is a family of proteins with multiple highly 190 
homologous isoforms. In some of these cases, a unique peptide cannot be detected in the dataset. Under 191 
these circumstances, the software selects a ‘winner’ based on which protein identification best explains 192 
the peptides observed. The quantification will be based on the peptides which are most discriminatory.  193 
Ratios were calculated from the areas under the curve for each iTRAQ reporter ion selecting 194 
different denominators depending on the comparisons to be made. Mean ratios were calculated based on 195 
all occurrences (up to 7) of all peptides for which there was a peptide confidence of >15% and where the 196 
protein was confidently identified through other evidence. Where a single peptide was used for 197 
quantification, the peptide confidence cut-off was 95%. Where a single peptide was used for 198 
identification, the cut-off was 99%. The Paragon algorithm performs a Student t-test on the unweighted 199 
log ratios (for background corrected data) and reports the p-value: for a final error rate of 5% and with 200 
1157 proteins quantified, the Bonferroni correction suggests a significant p-value at 0.0043. 201 
 202 
Bioinformatics analysis of secretion pathways 203 
The potential secretion pathways of proteins were predicted with the SecretomeP 2.0 server [15] 204 
(http://www.cbs.dtu.dk/services/SecretomeP/) for classical and nonclassical secretion. Protein sequences 205 
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were retrieved from the Uniprot database and uploaded onto the SecretomeP 2.0 server for prediction of 206 
protein secretion. Potential exosomal and microvesicle release of the proteins was studied by manual 207 
annotation on the ExoCarta exosome [16] (http://exocarta.ludwig.edu.au/) and Vesiclepedia [17] 208 
(http://microvesicles.org/index.html) databases.  209 
 210 
Ingenuity Pathway Analysis 211 
A bioinformatics approach was used to clarify the global implication of differentially secreted 212 
proteins in Panc1 cells and in Panc1 CSCs. The Ingenuity computational Pathway Analysis (IPA) 213 
(Ingenuity Systems, Redwood City, CA) software was applied to organize data into biological functions 214 
that are over represented, create molecular networks, and identify potentially perturbed molecular 215 
pathways. The IPA program uses a knowledge base derived from the literature to relate the proteins to 216 
each other based on their interaction and function. The knowledge base consists of a high-quality expert-217 
curated database containing 1.5 million biological findings, including more than 42,000 mammalian 218 
genes and pathway interactions extracted from the literature. In brief, Ingenuity uses the Core Analysis 219 
module to rank the proteins into top biological functions, networks, as well as canonical pathways 220 
involved. The IPA analysis settings were as follows: i) Reference set: Ingenuity Knowledge Base; ii) 221 
Relationship to include: Direct and Indirect; iii) Filter Summary: Consider only molecules and/or 222 
relationships where (species = Human) AND (confidence = Experimentally Observed). Proteins 223 
associated with canonical pathways were estimated as significant using Fisher’s exact test (p value < 224 
0.01) to determine the probability that the association between identified proteins and a canonical 225 
pathway could be explained by chance alone. 226 
 227 
Western Blot  228 
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Protein samples from two different biological replicates were diluted 1:1 with Laemmli’s sample 229 
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue), boiled for 3 min 230 
and separated by SDS/polyacrylamide gel electrophoresis (PAGE) on 12% T acrylamide gels in 231 
Tris/glycine/SDS buffer. Proteins were then electroblotted onto polyvinilydene fluoride membranes 232 
(Bio-Rad, Hercules, CA) at 60 V for 2 h at 4°C. Ponceau S staining was used to confirm equal protein 233 
loading in different lanes. Non-specific sites were blocked by incubating the membranes with 5% non-234 
fat dried milk and 0.05% Tween-20 (Sigma-Adrich) in Tris-buffered saline at 37°C for 45 min. 235 
Membranes were incubated with the different primary antibodies at the appropriate dilutions in 1% non-236 
fat dried milk, 0.05% Tween-20 in Tris-buffered saline for 3 h at room temperature. Blots were then 237 
incubated 45 min at room temperature with the appropriate horseradish peroxidase (HRP)-conjugated 238 
secondary antibody (see the Supplemental Table 1). The immunocomplexes were visualized by 239 
chemiluminescence using the Chemidoc MP imaging system (Bio-Rad Laboratories) and the intensity of 240 
the chemiluminescence response was measured by processing the image with Quantity One software 241 
Version 4.5 (Bio-Rad). 242 
 243 
Serum Samples 244 
The protocols used for this study were approved by the Verona University Hospital Ethics 245 
Committee with informed patient consent. Serum samples from PDAC patients (n = 100, 1-4 TNM 246 
stages) were obtained from the archives of the Pancreas Institute, ARC-NET biobank of the Verona 247 
University Hospital G.B. Rossi (www.arc-net.it). Clinicopathological characteristics of the considered 248 
PDAC patients are shown in Supplemental Table 2.  The healthy serum samples were obtained with 249 
informed consent from volunteers (n = 20) who received medical examinations at Verona University 250 
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Hospital G.B. Rossi.  The number of cases and controls were chosen according to studies previously 251 
described by others [18, 19]. 252 
 253 
All of the samples were collected following a standardized protocol. The serum samples were 254 
prepared by collecting blood in empty tubes, which were maintained at room temperature for a 255 
minimum of 30 min (and a maximum of 60 min) to allow clot formation, and then centrifuged at 3,000 x 256 
g for 10 min at 4°C. After centrifugation, the samples were divided into aliquots in cryotubes and 257 
immediately stored at -80°C until use. Samples were handled anonymously according to ethical and 258 
legal guidelines at the Verona University Hospital G.B. Rossi. 259 
 260 
ELISA assays of ceruloplasmin, galectin-3, MARCKS, and CA19-9 in human serum 261 
ELISA kits were purchased from Abcam Ltd (ceruloplasmin), eBioscience Bender (galectin-3), 262 
Sial s.r.l. (MARCKS), and DiaSorin (CA19-9). ELISA were carried out on 120 serum samples (100 263 
from pancreatic cancer and 20 from healthy individuals) using the recommended serum dilution and 264 
according to the instructions of the manufacturer.  The sensitivity of the ELISA kits for detection of 265 
ceruloplasmin, galectin-3, MARCKS, and CA19-9 was 0.6 µg/ml, 0.12 ng/ml, 15.6 pg/ml, and 0.30 266 
U/ml, respectively.  267 
 268 
Statistical analysis 269 
The relationship between clinical pathological variables and the level of target proteins was 270 
tested using either the Wilcoxon test or Kruskal-Wallis test. A one-tailed Student’s t test was performed 271 
assuming unequal variances to assess whether the means of healthy normal and PDAC groups were 272 
statistically different from each other. The candidates that showed a statistically significant difference (p 273 
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< 0.05) were evaluated by a receiver operating characteristic (ROC) curve, and then assessed in 274 
comparison to CA19.9. Multiparametric model for combination of ceruloplasmin and CA19-9 was 275 
constructed by fitting a logistic regression model on the marker concentrations. All data were processed 276 
using GraphPad Prism Software Version 6.0 (La Jolla, CA, USA). 277 
 278 
RESULTS 279 
Protein identification and quantification in Panc1 cell and Panc1 CSC conditioned media using 280 
iTRAQ 281 
The iTRAQ-labeled CM protein samples of Panc1 cells and Panc1 CSCs were analyzed together 282 
with their respective whole cell lysates as shown in Figure 1. A total of 2045 proteins with at least 283 
93.8% confidence and an Unused ProteinPilot scores > 1.09 (equating to a global FDR of 1%) were 284 
identified, among these a total of 1157 proteins were quantified with a peptide confidence cut-off of 285 
95% (Supplemental Table 3). Of these, 608 were identified via a single peptide with a confidence of 286 
99% (Supplemental Table 4).  287 
To select Panc1 and Panc1 CSC secreted proteins, the relative abundance of all the proteins in 288 
the CM of each sample was compared with that in the respective whole cell lysate. The cut-off for 289 
selecting the secreted proteins and those differentially secreted by Panc1 cells and Panc1 CSCs were 290 
chosen based on already published data [12].  Briefly, since proteins secreted by a cell should have a 291 
higher relative abundance in CM than in cell lysate, i.e. CM/Lysate ratio >1, to have a higher confidence 292 
on the secretion nature of the selected proteins, a cut-off >1.5 was used. In addition, only ratios that were 293 
reproducible in both biological replicates were taken into account [12]. One hundred and two and 73 294 
proteins were found to have CM/Lysate ratio >1.5 in Panc1 cells and Panc1 CSCs respectively, with an 295 
overlap of 63 proteins between the two cell types (Figure 2A). The identity of these 112 proteins, 296 
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together with their respective CM/Lysate ratios, is presented in Supplemental Table 5. Among the 112 297 
secreted proteins, 72 proteins were differentially secreted by Panc1 cells and Panc1 CSCs when a ratio 298 
cut-off >1.5 and <0.667 [12] was applied, 43 with higher accumulation in CM of Panc1 CSCs and 29 299 
with higher accumulation in CM of Panc1 cells (Tables 1 and 2).  300 
 301 
Mode of protein secretion  302 
To define if the 112 identified proteins were secreted by the classical or non-classical secretory 303 
pathways, we used the SecretomeP 2.0 prediction server. In addition, we used the Exocarta and 304 
Vesiclepedia databases, which contain proteins identified in exosomes and extracellular vesicles 305 
following non-classical secretory pathways. We found that 30 proteins (27%) were predicted to carry the 306 
N-terminal signal peptide that characterizes proteins of the classical secretory pathway, and 82 proteins 307 
(73%) were predicted to be secreted by non-classical pathways (Figure 2B). In summary, all the 112 308 
proteins considered to be secreted using a cut-off CM/Lysate ratio >1.5 in the secretome analysis [12], 309 
were confirmed as secreted proteins and have the potential to be addressed to the extracellular space by 310 
various mechanisms.  311 
 312 
Biological functions, pathway analyses, and interaction networks of secreted proteins 313 
To identify altered biological functions and pathways that might play a role in pancreatic cancer 314 
epithelial-mesenchymal transition (EMT) and/or metastasis, and to investigate the molecular networks 315 
involved, the 112 secreted proteins from Panc1 cells and Panc1 CSCs (indicated in Figure 2A, and 316 
listed in Supplemental Table 5) were analyzed using Ingenuity Pathway Analysis (IPA). In both 317 
secretomes, among all the proteins mapped by IPA's knowledgebase, proteins involved in functions such 318 
as cell death and survival, cellular movement, cellular growth and proliferation, cell morphology, and 319 
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cellular development were significantly over-represented (Table 3). In particular, the most relevant 320 
associated network functions (score > 40) were “cell death and survival, cellular movement, 321 
dermatological diseases and conditions” for Panc1 CSC secretome, and “cell death and survival, cell-to-322 
cell signaling and interaction, connective tissue development and function” and “cell death and survival, 323 
cancer, gastrointestinal disease” for Panc1 cell secretome. These network alterations associated with 324 
secreted proteins in Panc1 cells and Panc1 CSCs are illustrated in Supplemental Figure 1. 325 
We also performed canonical pathway analysis to determine over-represented signalling and 326 
metabolic pathways. Twenty-two and 15 canonical pathways were enriched in the Panc1 and Panc1 CSC 327 
secretomes, respectively (p-value ≤ 0.001) (Supplemental Table 6). The top 6 canonical pathways that 328 
included the secreted proteins of Panc1 cells and Panc1 CSCs are shown in Figure 3. Interestingly, 329 
glycolysis and gluconeogenesis were identified among the top hit list for both secretomes. 330 
 331 
Western Blot analysis of selected secreted proteins 332 
In order to validate mass spectrometry-based iTRAQ results, we selected 9 secreted proteins for 333 
Western Blot analysis These proteins were selected on the basis of several factors, such as CSCs over-334 
secretion, relevance to PDAC, and novelty. They included vinculin, ceruloplasmin, MARCKS, cathepsin 335 
D, glyceraldehyde-3-phosphate deydrogenase (GAPDH), 14-3-3 zeta and epsilon isoforms, galectin-3, 336 
and galectin-1. We compared the expression level of secreted proteins by Panc1 cells and Panc1 CSCs in 337 
two biological replicates. As shown in Figure 4, results from Western Blot analysis were in agreement 338 
with iTRAQ data. In particular, Panc1 CSCs were characterized by over-secretion of ceruloplasmin, 339 
galectin-3 and MARCKS that appeared to be absent in the secretome of the parental cell line. Similar 340 
results were obtained by analyzing ceruloplasmin in the secretome of three further CSC-like cell lines, 341 
MiaPaca2, PC1J, and PSN1 [6] (data not shown). Moreover, immunoblot results indicated that 342 
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MARCKS was secreted both as intact (~ 80 kDa) and cleaved (~ 40 kDa) forms, and cathepsin D was 343 
secreted as procathepsin D (45 kDa) and also as its mature form (30 kDa). 344 
 345 
Serum levels of ceruloplasmin, galectin-3, MARCKS, and CA19-9 in PDAC patients   346 
We performed on normal and pathological human sera an immunoassay-based analysis of highly 347 
secreted CSCs proteins and evaluated the potential of this determination to detect PDAC patients. 348 
Particularly, we focused our attention on the three proteins more secreted by Panc1 CSCs as compared 349 
to Panc1 cells (i.e. ceruloplasmin, galectin-3, and MARCKS), as well as on CA19-9, and verified their 350 
association with gender, age, histological grade, overall tumour stage, or TNM classification of PDAC. 351 
We found that serum levels of galectin-3 correlate with patient age, while serum levels of MARCKS 352 
correlate with patient gender (Supplemental Table 7). 353 
We tested and quantified the presence of ceruloplasmin, galectin-3, and MARCKS in PDAC 354 
patient sera by using commercially available ELISA (Figure 5). The analysis of serum samples (100 355 
cancer versus 20 healthy) showed significant higher levels (p < 0.01) of ceruloplasmin in PDAC (mean 356 
= 73.15 µg/ml, median = 63.50 µg/ml) in comparison to controls (mean = 57.13 µg/ml, median = 53.54 357 
µg/ml). In addition we found that serum levels of ceruloplasmin were significantly elevated in patients 358 
with PDAC at the early IIB stage (p < 0.01) and at stage III (p < 0.05) (Figure 5) compared to those in 359 
healthy control. In the same samples, MARCKS also showed significant (p < 0.05) elevation in cancer 360 
(mean = 149.45 pg/ml, median = 107.75 pg/ml) as compared to controls (mean = 110.89 pg/ml, median 361 
= 94.69 pg/ml), but there was no significant difference among patients with different PDAC stages 362 
(Figure 5). As concerning galectin-3 similar levels were present in patients (mean = 4.43 ng/ml, median 363 
= 4.10 ng/ml) and controls (mean = 4.61 ng/ml, median = 4.18 ng/ml) without significant difference 364 
among different stages (Figure 5). Serum levels of CA 19-9, a currently used serum PDAC biomarker, 365 
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were significantly higher (p < 0.05) in PDAC patients (mean = 1283.36 U/ml, median = 170.00 U/ml) 366 
than in healthy controls (mean = 8.76 U/ml, median = 6.50 U/ml). In addition CA19-9 also shown 367 
significant elevation in patients with PDAC stage IIB (p < 0.001), stage III (p < 0.05), and stage IV (p < 368 
0.05) (Figure 5). 369 
Receiver operating characteristic (ROC) curve analysis was carried out to evaluate the individual 370 
performance of ceruloplasmin, MARCKS and CA19-9 (Figure 6). This analysis showed lower AUCs 371 
for ceruloplasmin (AUC = 0.65; 95% CI: 0.54 – 0.76) and MARCKS (AUC = 0.56; 95% CI: 0.43 – 372 
0.70) in discriminating healthy controls from PDAC patients, in comparison with CA19-9 (AUC = 0.90, 373 
95% CI: 0.85 – 0.96). In particular, the AUC obtained for MARCKS indicates that it has virtually no 374 
discriminating power. Ceruloplasmin (cut-off = 60.75 µg/ml) has lower sensitivity (55%) than CA19-9 375 
(77%) in diagnosing PDAC. However, it is interesting to note that among the 25 patients with clinically 376 
low CA19-9 (< 37 U/ml), 14 (56%) were positive for ceruloplasmin (Supplemental Figure 2). 377 
Most importantly, a logistic regression model showed that the diagnostic capacity of the 378 
combination of ceruloplasmin and CA19-9 (AUC = 0.93; 95% CI: 0.88 – 0.97) was more discriminatory 379 
than CA19-9 alone (AUC = 0.90; 95% CI: 0.85 – 0.96). In addition, the combined predictor using 380 
information from both ceruloplasmin and CA19-9 showed increased sensitivity (83%) than CA19-9 381 
alone (77%).  382 
 383 
DISCUSSION 384 
The ability to identify and isolate CSCs in various tumour models has led to the possibility to 385 
study the mechanisms by which CSCs can contribute to tumour initiation as well as continued tumour 386 
progression. Up to now, a deep comprehension of CSC biology, and in particular that of pancreatic 387 
CSCs, is lacking. In the present study, a comparative secretome approach was taken to dissect the 388 
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differences in protein level between pancreatic cancer and pancreatic cancer stem cells. Secreted 389 
proteins are key mediators in cell-cell interactions and influence the cross talk with the surrounding 390 
tissues. Strong evidences support the idea that crucial cellular functions, such as proliferation, 391 
differentiation, communication, and migration, are strictly regulated by proteins secreted by the cells 
[20]
. 392 
Thus, the investigation of CSC secretome is extremely important to clarify the deregulated pathways 393 
involved in pancreatic cancer, but also to suggest possible new diagnostic markers.  For this purpose we 394 
have investigated the Panc-1 CSCs model that was previously characterized [6]. In particular, we have 395 
compared the secretome of CSCs with that of the parental cell line and we have identified the 396 
differentially secreted proteins, by applying a shotgun proteomic approach based on iTRAQ technology. 397 
Some of the most interesting differentially secreted proteins have also been validated by 398 
immunoblotting. Some of the Panc-1 CSCs over-secreted proteins identified in this study have already 399 
been reported in previous publications. In particular, 14-3-3 protein epsilon, 14-3-3 protein zeta/delta, 400 
annexin A5, glutathione S-transferase omega-1, plasminogen activator inhibitor 1, protein disulfide-401 
isomerase, and superoxide dismutase [Cu-Zn] were reported by Mateo et al. [11] as over-secreted by 402 
prostate CSCs and WD repeat domain 1 was reported by Emmink et al. [10] as over-secreted by colon 403 
CSCs.  404 
 405 
Deregulated pathways of the Panc1 CSC secretome 406 
The identified secreted proteins were overlaid with IPA-curated canonical pathways to explore 407 
possible metabolic and cell signalling pathways that are over-represented by the experimentally 408 
determined proteins. Despite some of the aberrant signalling pathways have been already identified in 409 
CSCs, like Hedgehog, Notch, Wnt/β-catenin, BMI1, PI3K/AKT, and Nodal/Activin [21, 22], and several 410 
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markers have been used to define CSCs, the signalling pathways regulating these events and markers 411 
remain not fully determined.  412 
Our analysis has shown that glycolysis and gluconeogenesis are the two most significant 413 
pathways in which the secreted proteins of both Panc1 cells and Panc1 CSCs are implicated (Figure 3). 414 
It has been largely demonstrated that the high glycolytic activity of PDAC and the consequent alteration 415 
of the glucose-connected metabolic pathways contribute to the progression and dissemination of the 416 
disease [23]. In addition, our findings further confirm that glycolytic and gluconeogenesis enzymes can 417 
be secreted by cells. Notably, it has been demonstrated that these enzymes perform non enzymatic, but 418 
rather structural or regulatory functions at the extracellular localization. For instance, in tumour cells the 419 
surface exposition of alpha-enolase (ENO1) acts as a plasminogen receptor, mediating plasmin 420 
activation, extracellular matrix degradation, and supporting anaerobic proliferation [24]. 421 
IPA analysis has also shown, among the significant pathways (p < 0.001) characterizing only the 422 
CSC secretome, the pentose phosphate (PP) pathway (non-oxidative branch), glioma invasiveness 423 
signalling, myc-mediated apoptosis signalling, ERK5 signalling, and remodelling of epithelial adherens 424 
junctions (Supplemental Table 6).  425 
The PP pathway plays a major role in stem cell biology, indeed, CSCs have been shown to 426 
possess a protective metabolic phenotype, mainly based on glycolysis and PP pathway, to scavenge 427 
reactive oxygen species (ROS) generated by oxidative metabolism [25]. It remains unclear why the PP 428 
enzymes are secreted and which function they have at the extracellular level. In particular, our study has 429 
shown that the CSC secretome is characterized by the presence of the PP enzyme transaldolase (> 1.93 430 
in CSC secretome compared to Panc1 secretome), which catalyses a non-oxidative phase reaction. 431 
Currently, the extracellular function of transaldolase has been clarified only for Bifidobacterium, where 432 
it has a role in mucin adhesion and cell aggregation [26]. Interestingly, it has been reported that mucins 433 
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play a key role in PDAC by enhancing tumourigenicity, invasiveness, metastasis and drug resistance 434 
[27].  435 
The glioma invasiveness signalling involves secreted proteins including 72 kDa type IV 436 
collagenase (MMP2), urokinase-type plasminogen activator (UROK/PLAU), and metalloproteinase 437 
inhibitor 2 (TIMP2). These three proteins, however, are not exclusive of the CSC secretome, but were 438 
also identified in the secretome of the Panc1 parental cell line (see Supplemental Table 5). 439 
Matrix metalloproteinase family plays a critical role in tumour cell invasion and metastasis. In 440 
particular, MMP2 secretion and activation, and the consequent increased tumour invasiveness, depend 441 
on ROS generation, which occurs after hypoxia-reoxygenation of Panc1 cells [28]. Recently, it has also 442 
been demonstrated that reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic 443 
cancer through the Hedgehog signalling, a peculiar pathway of pancreatic CSCs [29]. Moreover, 444 
stimulation of Panc1 cells with bone morphogenetic proteins (BMP2) induces MMP2 secretion and 445 
activation, in association with decreased expression of E-cadherin (an invasion suppressor), and leads to 446 
EMT and cell invasion [30]. TIMPs are naturally occurring inhibitors of MMPs that inhibit the MMP 447 
activity and hence restrict breakdown of ECM, maintains connective tissue integrity, thus slow down 448 
carcinogenesis, tumour invasion and metastasis. Disturbance in balance of MMPs and TIMPs is found in 449 
associated with various pathologic conditions including cancer. Interestingly, sequence variants of 450 
TIMP2 (TIMP2c.418G>C variants), are associated with the development of tumour growth and 451 
progression [31], this may be because of low promoter activity for TIMP-2 expression, resulting in slow 452 
inhibition of MMPs, leading to inflammatory microenvironment and carcinogenesis. Also UROK is 453 
involved in the degradation of the extracellular matrix, tumour cell migration and proliferation. It 454 
converts plasminogen to plasmin, which in turn can degrade a wide variety of extracellular matrix 455 
components and enable the tumour cells to penetrate the basement membrane. The induced expression in 456 
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PDAC of this protease depends on the activation of the EGFR/NF-κB axis, which is mediated by the 457 
oncogene K-Ras and loss of Smad4 [32].  458 
It is interesting to note that two other pathways characteristic of CSC secretome, i.e. myc-459 
mediated apoptosis signalling and ERK5 signalling, involve the 14-3-3 proteins. Recently, it has been 460 
proved that 14-3-3 proteins are secreted, together with β-catenin, via extracellular vesicles to activate 461 
the oncogenic Wnt pathway [33], which is a peculiar pathways of CSCs. It is known that as a result of 462 
uptake of 14-3-3 containing-exosomes, the oncogenic Wnt pathway becomes activate also in 463 
surrounding cells. Moreover, it has been demonstrated that 14-3-3protein is involved in EMT in lung 464 
[34], as well as in breast [35] cancer, while both isoforms 14-3-3and are involved in Ein 465 
hepatocellular carcinoma [36]. 466 
Another pathway characteristic of the CSC secretome is the “remodelling of epithelial adherens 467 
junctions” which comprises nucleoside diphosphate kinase A (NDKA/NME1), vinculin (VINC/VCL), 468 
and alpha-actinin-4 (ACTN4). Vinculin is a highly conserved actin-binding protein that is localized in 469 
integrin-mediated focal adhesion complexes and is indispensable for hematopoietic stem cell 470 
repopulation [37]. In particular, vinculin has a key role in the molecular mechanisms that sense 471 
extracellular matrix stiffness, which is known to direct the lineage specification of stem cells and to 472 
affect cancer progression [38]. Alpha-actinin-4 is a cell motility–associated actin-binding protein that 473 
has a tumour-promoting potential in PDAC [39]. Interestingly, it forms a complex with -catenin in the 474 
absence of E-cadherin and mediates cancer invasion and metastasis [40]. 475 
Evaluation of the potential use as biomarkers of ceruloplasmin, galectin-3, and MARCKS 476 
Among the identified proteins, we selected ceruloplasmin, galectin-3 and MARCKS for further 477 
evaluation of their clinical relevance in PDAC. 478 
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Ceruloplasmin is the major copper-carrying protein in the blood, with both anti- and pro-oxidant 479 
activities. It can be expressed as a membrane glycosylphosphatidylinositol-anchored protein, or can be 480 
secreted by a classical mechanism involving a single peptide [41]. Ceruloplasmin levels are reported to 481 
be increased in sera of patients with various acute inflammatory conditions, including injury, 482 
malignancy, cardiovascular disease, and infection [42]. Also in PDAC patients ceruloplasmin appears to 483 
be increased as detected by a liquid ESI-MS analysis [43]. It has been suggested that the increased 484 
presence of ceruloplasmin in the sera of pancreatic cancer patients is consistent with the overall 485 
hypothesis that pancreatic cancer has an inflammatory disease component. Tobacco smoke and alcohol 486 
are in fact known risk agents for pancreatic cancer. 487 
Here, we show that ceruloplasmin is strongly increased in CSCs secretome (>15.93) compared to 488 
the parental cell line. Accordingly, this protein has been found enriched also in secretomes of other 489 
CSCs, in particular malignant glioma stem-like cells, where its production is regulated by hyaluronan, 490 
which interacts with CD44 receptors, also present on pancreatic CSCs [44]. Ceruloplasmin acts as a 491 
ferroxidase, an enzyme essential for normal iron homeostasis, which plays a critical role in EMT [45]. In 492 
addition, concentration of ceruloplasmin was significantly higher in the ascites fluids of chemoresistant 493 
ovarian cancer patients [46]. In parallel, CSC over-secretion of ceruloplasmin detected in our samples 494 
may correlate with the known resistance to gemcitabine chemotherapy in pancreatic cancer. Indeed, the 495 
observation that gemcitabine induces apoptosis by raising intracellular ROS levels let to hypothesis that 496 
secreted ceruloplasmin may lead to chemoresistance by decreasing ROS levels. We showed that 497 
ceruloplasmin could discriminate controls from PDAC patients and, remarkably, also patients at the 498 
early stages (Figure 5).  499 
It should be pointed out that differentially expressed or secreted candidates are sometimes a result of the 500 
generic acute phase reactions, which should not be misinterpreted as promising markers. Hence, as a 501 
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general rule, the identification of a combination of biomarkers is considered to be much more effective 502 
for detection of specific cancer. To this end, we investigated the performance of ceruloplasmin in 503 
combination with CA19-9. We found that the combination of CA19- 9 and ceruloplasmin improve the 504 
AUC of CA19-9 alone (Figure 6) and that ceruloplasmin levels were higher than controls in more than 505 
50% of patients negative for CA19-9. These findings suggest that ceruloplasmin might prove to be a 506 
valuable complementary biomarker for CA19-9. 507 
Galectin-3 is a 30 kDa galactoside-binding protein expressed in several cell types and is involved 508 
in a broad range of physiological and pathological processes, especially in regulating cancer cell 509 
activities [47]. Indeed, galectin-3 has been widely demonstrated to be involved in malignant cell 510 
transformation, tumour growth, anoikis resistance, apoptosis inhibition, chemoresistance, angiogenesis, 511 
cell adhesion, cell motility, and cell invasion [48]. The latter four events are important steps of the 512 
metastatic process, in which secreted galectin-3 plays a key role in both tumour and stromal cells of the 513 
tumour microenvironment [49]. Here, we show that galectin-3 is over-secreted by CSCs (>12.59 514 
compared to parental cells). Up to now, the non-classical mechanism for galectin-3 secretion is not clear, 515 
but data obtained so far suggest that galectin-3 is secreted via exosomes [50]. This protein has already 516 
been found as secreted by other stem cells, for example mesenchymal stem cells to induce suppression 517 
of T-cell proliferation [51], consistent with its involvement in tumour-immune-escape mechanisms. 518 
Interestingly, galectin-3 is also implicated in the pathogenesis of PDAC [52]. In a recent study, it has 519 
been demonstrated that galectin-3 is directly associated with the oncogene K-Ras and contributes to its 520 
activation in pancreatic cancer cells [53]. Furthermore, it has been shown that transient silencing of 521 
galectin-3 suppresses PDAC malignant behaviour [54], suggesting a functional role in PDAC tumour 522 
progression and invasion. The clinical significance of serum galectin-3 in pancreatic carcinoma is 523 
currently not fully clarified. The available data are conflicting: it has been demonstrated to be higher in 524 
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serum of PDAC patients as compared to controls [55], although a separate study showed it to be 525 
unchanged between these groups [56]. For this reason, given that galectin-3 was highly elevated in the 526 
secretome of Panc1 CSCs, we tested its levels in our screening set of serum samples by ELISA and 527 
found that there was no significant increase in levels in pancreatic cancer sera versus controls (Figure 528 
5). 529 
The third most abundant CSC secreted protein is MARCKS. MARCKS, a major phosphorylation 530 
target for protein kinase C, is typically membrane-bound through a lipid anchor at the N-terminus, and a 531 
polybasic domain in the middle, however, it has also already been found in cell secretome of colorectal 532 
cancer metastatic cells [57]. MARCKS is a key regulatory molecule controlling mucus granule secretion 533 
by airway epithelial cells, as well as directed migration of leukocytes, fibroblasts and mesenchymal stem 534 
cells [58]. Recently, it has been demonstrated that a peptide that inhibits MARCKS function reduces 535 
lung cancer metastasis [59]. However, MARCKS has been reported in glioma and melanoma cells to 536 
possess not only a pro-metastatic [60, 61] but also a growth suppressor activity [62, 63]. Interestingly, 537 
MARCKS was found to have a strikingly higher expressed transcript in pancreatic cancer cell lines with 538 
a mutated K-Ras (Panc1, Capan-2, and MiaPaCa2) in comparison to pancreatic cancer cell lines with the 539 
wild-type K-Ras gene (Hs766T and BxPC-3) [64]. Accordingly, a severe decrease in MARCKS 540 
expression has been shown to correlate with Ras reversion [65]. Our results indicate that MARCKS is 541 
over-secreted (> 10.79) by CSCs relative to parental cells. However, even if the verification analysis 542 
performed on the sera showed that this marker discriminates between controls and PDAC patients 543 
(Figure 5), the ROC curve indicated that it does not have diagnostic accuracy (Figure 6). 544 
In conclusion, our Panc1 and Panc1 CSCs secretome analysis revealed a large number of 545 
secreted proteins, which participate in pathological conditions including cancer differentiation, invasion 546 
and metastasis. The identified proteins may serve as a valuable pool of proteins from which cancer 547 
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biomarkers and or therapeutic targets can be identified. Among the highly CSC secreted proteins, 548 
ceruloplasmin looks promising and further validation in bigger cohorts of patients and healthy controls 549 
is hopeful. 550 
 551 
  552 
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Figure Legends  707 
Figure 1. Schematic representation of the experimental design for iTRAQ labeling showing biological 708 
replicates. Samples were trypsinized prior to iTRAQ labeling, and the labeled peptides were then mixed, 709 
separated by 2D-LC, and identified by MS/MS. Database search and iTRAQ analysis were performed 710 
using the ProteinPilot software (Version 4.2) from AB SCIEX.  711 
 712 
Figure 2. Secretome of Panc1 cells and Panc1 CSCs. (A) Venn diagram showing the number of proteins 713 
with CM/Lysate ratio >1.5 that were identified in Panc1 cells and Panc1 CSCs. The intersection 714 
indicates the number of proteins secreted by both cell lines. (B) SecretomeP prediction of the proteins 715 
with CM/Lysate ratio >1.5. Amino acid sequences of these proteins were retrieved from Uniprot and 716 
imported into the SecretomeP 2.0 server for prediction of mode of secretion. 717 
 718 
Figure 3. The top 6 signalling pathways that significantly (p < 0.001) characterize the secretome of (A) 719 
Panc1 (B) and Panc1 CSCs data sets. Bioinformatics analyses were performed using IPA software. 720 
The pathways are ranked by p value, which is a measure of significance of the changes induced in the 721 
secretome. The threshold corresponds to the significance at 95% confidence. The ratio is calculated as 722 
follows: the number of molecules in a given pathway that meet cut-off criteria, divided by total number 723 
of molecules that make up that pathway. 724 
 725 
Figure 4. Confirmation of iTRAQ results by Western blot. Proteins from conditioned media were 726 
resolved in 10-20% SDS-PAGE gels, transferred onto PVDF membranes, and probed with specific 727 
antibodies against the indicated targets. Ponceau S stained blot is shown to demonstrate 728 
equal loading. 729 
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Figure 5. Ceruloplasmin, MARCKS, galectin-3, and CA19-9 concentration blood sera. Analysis of 730 
serum concentrations were determined in serum samples of PDAC patients (n = 100) and healthy 731 
controls (n = 20). The levels of the four proteins were measured in patients at different TNM stages. As 732 
regarding ceruloplasmin there were significant difference between controls and the early IIB stage (p < 733 
0.01), and stage III (p < 0.05). For CA19-9 there were significant difference between controls and the 734 
early IIB stage (p < 0.001), stage III (p < 0.05), and stage IV (p < 0.05). For MARCKS and galectin-3 735 
there were no significant differences among different stages. Data are represented in dot plots, horizontal 736 
bar represents the median of the ELISA value data set. * = p value < 0.05; ** = p value < 0.01; *** = p 737 
value <0.001. 738 
 739 
Figure 6. Receiver Operating Characteristic curve analysis for Ceruloplasmin, MARCKS and CA19.9. 740 
AUC (area under curve) is given at 95% confidence intervals (CI). AUC of ceruloplasmin, MARCKS, 741 
and CA19.9 is depicted individually in this sample set of 20 controls and 100 PDAC. The combination 742 
of ceruloplasmin with CA19.9 shows improved AUC to CA19.9 alone.  743 
 744 
 745 
 746 
 747 
 748 
 749 
 750 
 751 
 752 
Table 1. Secreted proteins with higher abundance in the CM of Panc1 CSCs compared to Panc1 cells. 753 
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 754 
a
 Average of four iTRAQ CM CSC / CM Panc1 ratios, i.e. 116/114, 121/118, 116/118, and 121/114. The ratios were followed by the corresponding standard 755 
deviation (sd). 
b
 SecretomeP prediction for non-classical secretion (NC). Classically secreted proteins would contain the N-terminal signal peptide (SP) 756 
while proteins predicted to be neither classically nor non-classically secreted were further analyzed by Exocarta and Vesiclepedia. 
c
 Prediction of exosomal 757 
release via manual annotation against the Exocarta database. Proteins that were not classically secreted and were present in the database were labeled 758 
“present”. 
d
 Prediction of extracellular vesicles release via manual annotation against the Vesiclepedia database. Proteins that were not classically secreted 759 
and were present in the database were labeled “present”.  760 
 761 
 762 
  763 
Name Unused Total
% Seq 
Coverage
(95)
UniProt/Swiss
Prot 
Accession
Peptides 
(> 93.8%)
Peptides 
used for 
quant
Average CM 
CSCs / Panc1 
(>1.5) a
sd SecretomeP b ExoCarta c Vesiclepedia d
Ceruloplasmin 9.1 9.29 7.32 P00450 6 4 15.93 3.26 SP
Galectin-3 13.95 13.95 27.20 P17931 7 36 12.59 1.44 NC
Myristoylated alanine-rich C-kinase substrate 26.44 26.48 56.02 P29966 15 49 10.79 3.04 present
Transaldolase 17.08 18.56 24.04 P37837 9 35 6.10 1.93 present
Galectin-1 19.37 19.4 62.96 P09382 11 102 5.63 0.26 present
Insulin-like growth factor-binding protein 7 8.03 8.03 19.50 Q16270 4 11 5.26 0.59 SP
Glyceraldehyde-3-phosphate dehydrogenase 49.39 49.39 62.09 P04406 26 140 5.18 0.51 present
Cytosolic non-specific dipeptidase 13.01 13.06 15.37 Q96KP4 7 9 4.95 1.94 present
Tyrosine--tRNA ligase, cytoplasmic 25.09 26.14 25.00 P54577 13 10 4.65 1.07 present
Phosphoglucomutase-1 23.02 23.37 28.83 P36871 12 6 4.52 2.84 present
Non-histone chromosomal protein HMG-14 10.53 10.53 51.00 P05114 6 23 4.36 2.09 present
Chloride intracellular channel protein 1 20.77 21.39 63.49 O00299 11 35 4.24 1.47 present
Glutathione S-transferase P 16.15 17.03 52.38 P09211 8 22 4.00 1.86 NC
Lactoylglutathione lyase 5.8 5.81 14.67 Q04760 4 8 3.95 1.85 present
Vinculin 88.07 89.75 42.24 P18206 46 150 3.92 0.36 present
Protein DJ-1 22.7 24.19 59.79 Q99497 10 31 3.35 0.54 present
Thioredoxin 4.08 4.11 20.95 P10599 2 18 3.03 0.55 present
14-3-3 protein epsilon 15.85 22.52 55.29 P62258 9 48 3.03 0.08 present
60S acidic ribosomal protein P2 22.12 22.58 76.52 P05387 13 45 2.82 0.66 present
Cathepsin D 31.44 33.44 44.66 P07339 19 74 2.76 1.12 SP
L-lactate dehydrogenase B chain 21.34 27.05 44.31 P07195 14 81 2.73 0.17 NC
T-complex protein 1 subunit beta 40.95 43.05 52.34 P78371 21 55 2.69 0.88 NC
Fructose-bisphosphate aldolase A 51.66 51.66 67.58 P04075 29 94 2.58 0.05 present
Glutathione S-transferase omega-1 10.54 10.71 20.33 P78417 6 29 2.53 0.56 present
Myosin light polypeptide 6 17.82 17.91 62.25 P60660 10 38 2.52 0.52 present
Bifunctional purine biosynthesis protein PURH 21.8 22.16 25.17 P31939 11 12 2.50 0.38 present
Peroxiredoxin-1 21.75 21.82 49.25 Q06830 12 65 2.36 0.24 NC
Coactosin-like protein 12.16 12.34 42.96 Q14019 7 21 2.35 0.41 NC
Transketolase 32.71 34.5 30.50 P29401 20 50 2.23 0.04 present
Phosphoglycerate mutase 1 14.1 14.17 31.10 P18669 8 28 2.11 0.41 present
Alpha-actinin-4 110.54 110.54 61.25 O43707 53 187 2.09 0.49 present
Superoxide dismutase [Cu-Zn] 6.32 6.32 25.32 P00441 4 12 2.02 0.33 NC
Elongation factor 1-beta 11.48 13.47 24.89 P24534 5 27 2.02 0.63 NC
14-3-3 protein zeta/delta 31.93 32.22 60.82 P63104 16 67 1.95 0.14 present
Adenylyl cyclase-associated protein 1 17.87 17.96 20.42 Q01518 8 34 1.91 0.36 present
L-lactate dehydrogenase A chain 30.52 30.76 45.78 P00338 15 112 1.84 0.13 NC
Alpha-actinin-1 15.89 52.15 33.41 P12814 12 6 1.83 1.17 present
Galectin-3-binding protein 23.78 24.24 22.39 Q08380 12 28 1.82 0.24 SP
Cofilin-1 26.23 26.58 79.52 P23528 14 128 1.76 0.22 NC
Importin subunit beta-1 34.77 36.42 27.97 Q14974 18 26 1.72 0.38 NC
Triosephosphate isomerase 32.93 32.93 63.29 P60174 18 97 1.60 0.05 NC
Non-histone chromosomal protein HMG-17 5.02 5.02 22.22 P05204 3 9 1.57 0.40 NC
Heat shock 70 kDa protein 4 39.86 41.48 33.93 P34932 20 12 1.55 0.61 present
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Table 2. Secreted proteins with higher abundance in the CM of Panc1 cells compared to Panc1 CSCs. 764 
 765 
a
 Average of four iTRAQ CM CSC / CM Panc1 ratios, i.e. 116/114, 121/118, 116/118, and 121/114. The ratios were followed by the corresponding standard 766 
deviation (sd). 
b
 SecretomeP prediction for nonclassical secretion (NC). Classically secreted proteins would contain the N-terminal signal peptide (SP) while 767 
proteins predicted to be neither classically nor nonclassically secreted were further analyzed by Exocarta and Vesiclepedia. 
c
 Prediction of exosomal release 768 
via manual annotation against the Exocarta database. Proteins that were not classically secreted and were present in the database were labeled “present”.  769 
  770 
Name Unused Total
% Seq 
Coverage 
(95)
UniProt/Swiss
Prot Accession
Peptides 
(> 93.8%)
Peptides 
used for 
quant
Average CM 
CSCs/ Panc1 
(< 0.667) a
sd SecretomeP b ExoCarta c 
Alpha-2-HS-glycoprotein 6 7.28 6.81 P02765 3 27 0.02 0.01 SP
Lactadherin 12.36 12.67 24.81 Q08431 7 8 0.03 0.01 SP
Serum albumin 39.03 39.77 28.41 P02768 19 104 0.03 0.00 SP
Alpha-2-macroglobulin 6.83 8.35 2.17 P01023 3 5 0.03 0.02 SP
Plasminogen activator inhibitor 1 33.24 33.47 45.02 P05121 18 67 0.08 0.03 SP
Brain acid soluble protein 1 26.36 26.36 78.41 P80723 13 113 0.09 0.02 present
Neural cell adhesion molecule L1 8.61 10.24 7.56 P32004 7 2 0.10 0.04 SP
Transforming growth factor-beta-induced protein ig-h3 15.94 18.78 15.52 Q15582 9 28 0.11 0.02 SP
Collagen alpha-1(XVIII) chain 25.83 26.68 10.43 P39060 14 24 0.12 0.06 SP
Urokinase-type plasminogen activator 9.01 9.4 12.99 P00749 5 5 0.14 0.06 SP
ADM 2.04 2.04 5.95 P35318 1 2 0.19 0.02 SP
Protein FAM3C 7.47 7.51 22.47 Q92520 4 5 0.19 0.05 NC
Transgelin-2 19.51 19.51 57.29 P37802 10 9 0.28 0.20 NC
Dystroglycan 11.73 12.06 8.94 Q14118 6 14 0.32 0.04 SP
Laminin subunit beta-1 14.52 21.37 5.04 P07942 7 4 0.37 0.06 SP
Metalloproteinase inhibitor 2 4.91 4.96 16.82 P16035 4 5 0.39 0.12 SP
Calsyntenin-1 11.61 11.96 8.16 O94985 8 17 0.39 0.11 SP
Lysyl oxidase homolog 2 2.58 2.68 2.20 Q9Y4K0 2 2 0.39 0.24 SP
Clusterin 20.35 20.76 25.84 P10909 11 55 0.40 0.03 SP
Hsp90 co-chaperone Cdc37 7.74 7.98 15.34 Q16543 4 4 0.41 0.25 present
Serotransferrin 27.82 28.14 21.78 P02787 15 23 0.46 0.11 SP
Heat shock protein HSP 90-alpha 22.36 54.62 33.74 P07900 11 39 0.54 0.29 present
Apolipoprotein E 21.96 22.06 41.32 P02649 11 5 0.54 0.07 SP
Plasminogen activator inhibitor 1 RNA-binding protein 12.05 12.13 18.38 Q8NC51 6 18 0.57 0.36 present
Annexin A5 38.6 38.6 55.62 P08758 19 120 0.57 0.10 NC
Keratin, type II cytoskeletal 2 epidermal 11.71 16.09 12.99 P35908 6 4 0.58 0.14 present
Gelsolin 23.88 24.04 20.84 P06396 11 5 0.59 0.02 SP
Keratin, type II cytoskeletal 1 7.69 17.9 12.11 P04264 5 10 0.63 0.05 present
Nucleobindin-1 22.21 24 29.93 Q02818 12 32 0.65 0.18 SP
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Table 3. IPA-predicted top biological functions for Panc1 and Panc1 CSC secretomes.  771 
Top biological functions (Panc1 secretome) 
 
p  values 
a
 
(ranging from) 
No. of 
molecules 
b
 
Disease and disorders   
Dermatological Diseases and Conditions 5.08E-16 - 6.06E-03 36 
Cancer 5.74E-11 - 9.51E-03 80 
Gastrointestinal Disease 5.74E-11 - 8.90E-03 50 
Hepatic System Disease 5.74E-11 - 6.64E-03 16 
Organismal Injury and Abnormalities 3.53E-10 - 9.20E-03 57 
Molecular and cellular functions   
Cell Death and Survival 1.51E-16 - 8.46E-03 49 
Cellular Growth and Proliferation 1.07E-14 - 9.51E-03 52 
Cellular Movement 4.16E-11 - 9.16E-03 35 
Cellular Development 1.07E-09 - 9.51E-03 38 
Cell Morphology 6.05E-07 - 6.43E-03 31 
Physiological System Developement and Fucntion 
Organismal Survival 7.84E-09 - 7.84E-09 13 
Cardiovascular System Development and Function 6.05E-07 - 9.51E-03 14 
Organismal Development 6.05E-07 - 8.13E-03 21 
Tissue Development 6.05E-07 - 8.13E-03 28 
Hematological System Development and Function 5.51E-05 - 9.16E-03 14 
   
Top biological functions (Panc1 CSC secretome) 
 
p  values  
(ranging from) 
No. of 
molecules  
Disease and disorders   
Dermatological Diseases and Conditions 6.60E-13 - 8.55E-03 27 
Metabolic Disease 1.69E-10 - 1.28E-02 26 
Neurological Disease 1.32E-09 - 1.28E-02 34 
Psychological Disorders 1.32E-09 - 8.55E-03 33 
Cancer 1.41E-09 - 1.28E-02 54 
Molecular and cellular functions   
Cell Death and Survival 6.63E-12 - 1.28E-02 35 
Cellular Movement 4.73E-09 - 1.28E-02 25 
Cellular Growth and Proliferation 1.05E-07 - 1.06E-02 32 
Cell Morphology 1.49E-07 - 1.28E-02 28 
Cellular Development 1.49E-07 - 9.81E-03 23 
Physiological System Developement and Fucntion 
Cardiovascular System Development and Function 1.49E-07 - 1.03E-02 12 
Organismal Development 1.49E-07 - 1.04E-02 19 
Tissue Development 1.49E-07 - 1.28E-02 23 
Organismal Survival 1.98E-06 - 3.64E-03 11 
Hematological System Development and Function 4.14E-05 - 1.12E-02 10 
 772 
a
 Fisher’s exact test was used to calculate a p value for each protein of the dataset identified in the biological function studied, indicating the probability that 773 
each biological function assigned to the data set is assigned by chance; then we have a range of p values corresponding to all p values calculated for all 774 
proteins of the dataset in the biological function. 
b 
The number of molecules of the differentially released protein dataset is shown. 775 
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